- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
Transition Therapeutics Inc
+ Add to WatchlistTTHI:US
3.1000 USD 0.0400 1.31%As of 20:10:00 ET on 05/24/2013.
Snapshot for Transition Therapeutics Inc (TTHI)
| Open: | 3.0600 | Day's Range: | 2.9900 - 3.1099 | Volume: | 18,564 |
|---|---|---|---|---|---|
| Previous Close: | 3.1000 | 52wk Range: | 1.7800 - 3.8399 | 1-Yr Rtn: | +53.46% |
Key Statistics for TTHI
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(06/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (CAD) (ttm) | - |
| Est. EPS (CAD) (06/2013) | -0.0330 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 83.46 |
| Shares Outstanding (M) | 26.92 |
| 30 Day Average Volume | 135,435 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 09/13/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for TTHI
Company Profile & Key Executives for TTHI
Transition Therapeutics Inc. is a biopharmaceutical company focused on developing novel therapeutics in order to address global medical needs in large disease indications, including Alzheimer's disease and diabetes.
| Tony F CruzChairman/CEO | Nicole Rusaw GeorgeChief Financial Officer |
| Aleksandra PastrakVP:Clinical Dev/Medical Ofcr | Carl DamianiVP:Business Development |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
TTHI News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page